Vaccines, Blood & Biologics

Influenza Virus Vaccine for the 2014-2015 Season

Cumulative 2014/2015 Season Lot Release Status (Updated 9/24/2014)
Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.
 

ManufacturerTotal Number of Lots Released by FDA
AFLURIA
CSL Limited
42
Fluarix
GlaxoSmithKline Biologicals
3
Fluarix - Quadrivalent
GlaxoSmithKline Biologicals
27
Flucelvax,
Novartis Vaccines and Diagnostics, Inc.
16
FluLaval
ID Biomedical Corp. of Quebec
5
FluLaval Quadrivalent
ID Biomedical Corp.
11
FluMist Quadrivalent
MedImmune, LLC
19
Fluvirin
Novartis Vaccines and Diagnostics Limited
52
Fluzone
Sanofi Pasteur, Inc.
26
Fluzone Quadrivalent
Sanofi Pasteur, Inc.
24


FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on February 28, 2014, to select the influenza viruses for the composition of the influenza vaccine for the 2014-2015 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2013-2014 vaccines, and the availability of candidate strains and reagents.

The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2014-2015 influenza season contain the following:

  • an A/California/7/2009 (H1N1)-like virus;
  • an (H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011;
  • a B/Massachusetts/2/2012-like virus.

The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:

  • a B/Brisbane/60/2008-like virus

 

Page Last Updated: 09/24/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.